Tenax Therapeutics (TENX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	98.31 mm	98.31 mm	98.31 mm	98.31 mm	98.31 mm	98.31 mm
Cash burn (monthly)	(no burn)	(no burn)	(no burn)	(no burn)	1.03 mm	184.71 k
Cash used (since last report)	n/a	n/a	n/a	n/a	5.21 mm	935.61 k
Cash remaining	n/a	n/a	n/a	n/a	93.10 mm	97.38 mm
Runway (months of cash)	n/a	n/a	n/a	n/a	90.5	527.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

TENX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	18	6	+200.0%
Opened positions	14	1	+1300.0%
Closed positions	2	7	-71.4%
Increased positions	1	0	NEW
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	1.88 bn	36.67 mm	+5021.6%
Total shares	12.17 mm	790.63 k	+1439.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Vivo Opportunity Fund	6.25 mm	$25.88 mm	NEW
T. Rowe Price	3.75 mm	$14.74 mm	NEW
Intracoastal Capital	479.73 k	$840.00 k	0.0%
Adage Capital Management	369.10 k	$1.59 mm	NEW
Venrock Healthcare Capital Partners III	355.22 k	$1.47 mm	NEW
Biotechnology Value Fund L P	340.66 k	$1.41 mm	NEW
Vivo Capital	208.33 k	$720.83 mm	NEW
Stuart Rich	95.48 k	$142.00 k	0.0%
Adage Capital Partners GP, L.L.C.	83.33 k	$288.33 mm	NEW
Velan Capital Investment Management	83.33 k	$288.33 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Vivo Opportunity Fund	6.25 mm	+6.25 mm	NEW
T. Rowe Price	3.75 mm	+3.75 mm	NEW
Adage Capital Management	369.10 k	+369.10 k	NEW
Venrock Healthcare Capital Partners III	355.22 k	+355.22 k	NEW
Biotechnology Value Fund L P	340.66 k	+340.66 k	NEW
Vivo Capital	208.33 k	+208.33 k	NEW
CVI Investments	0.00	-204.03 k	EXIT
Adage Capital Partners GP, L.L.C.	83.33 k	+83.33 k	NEW
Velan Capital Investment Management	83.33 k	+83.33 k	NEW
ADAR1 Capital Management	62.42 k	+62.42 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TENX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
10 Dec 24	June Sherie Almenoff	Stock Option Common Stock	Grant	Acquire A	No	No	5.94	100,000	594.00 k	100,000
10 Dec 24	Michael H. Davidson	Stock Option Common Stock	Grant	Acquire A	No	No	5.94	100,000	594.00 k	100,000
10 Dec 24	Doogan Declan	Stock Option Common Stock	Grant	Acquire A	No	No	5.94	100,000	594.00 k	100,000
10 Dec 24	Robyn Hunter	Stock Option Common Stock	Grant	Acquire A	No	No	5.94	100,000	594.00 k	100,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Thursday's Pre-Market Session

16 Jan 25

Press releases

From Benzinga Pro

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

31 Jan 25

CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying,